Natixis Advisors LLC Buys 9,072 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Key Points

• Natixis Advisors LLC increased its stake in Exelixis, Inc. by 14.9%, adding 9,072 shares during the first quarter, bringing its total holdings to 69,922 shares valued at approximately $2.58 million.
• Multiple institutional investors have recently acquired shares in Exelixis, with 85.27% of the stock now owned by hedge funds and other institutional investors.
• Exelixis has received varied ratings from analysts, maintaining a consensus rating of "Moderate Buy" and a target price of $44.44, while reporting significant earnings and revenue figures that diverged from projections.

Natixis Advisors LLC raised its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 14.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,922 shares of the biotechnology company's stock after acquiring an additional 9,072 shares during the quarter. Natixis Advisors LLC's holdings in Exelixis were worth $2,582,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its stake in Exelixis by 6.1% in the first quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company's stock valued at $195,000 after acquiring an additional 307 shares during the last quarter. Balyasny Asset Management L.P. lifted its stake in shares of Exelixis by 1.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company's stock worth $573,000 after buying an additional 317 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of Exelixis by 9.2% during the 1st quarter. Larson Financial Group LLC now owns 4,367 shares of the biotechnology company's stock worth $161,000 after buying an additional 367 shares during the last quarter. Sterling Capital Management LLC lifted its stake in shares of Exelixis by 7.8% during the 4th quarter. Sterling Capital Management LLC now owns 6,627 shares of the biotechnology company's stock worth $221,000 after buying an additional 477 shares during the last quarter. Finally, Comerica Bank lifted its stake in shares of Exelixis by 0.6% during the 4th quarter. Comerica Bank now owns 87,681 shares of the biotechnology company's stock worth $2,920,000 after buying an additional 544 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on EXEL shares. Royal Bank Of Canada lowered their price target on shares of Exelixis from $50.00 to $45.00 and set a "sector perform" rating on the stock in a research report on Tuesday, July 29th. JMP Securities reaffirmed a "market outperform" rating and set a $50.00 price target on shares of Exelixis in a research report on Tuesday, July 29th. Wall Street Zen lowered shares of Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 2nd. Jefferies Financial Group set a $50.00 price target on shares of Exelixis and gave the stock a "buy" rating in a research report on Tuesday, June 24th. Finally, Truist Financial lowered their price target on shares of Exelixis from $56.00 to $49.00 and set a "buy" rating on the stock in a research report on Tuesday, July 29th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat, Exelixis has a consensus rating of "Moderate Buy" and a consensus target price of $44.44.

Insider Transactions at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $46.18, for a total transaction of $1,154,500.00. Following the transaction, the executive vice president directly owned 693,396 shares in the company, valued at $32,021,027.28. This trade represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 126,383 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the transaction, the executive vice president owned 446,459 shares in the company, valued at $21,412,173.64. The trade was a 22.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 456,605 shares of company stock valued at $20,966,005. Corporate insiders own 2.82% of the company's stock.

Exelixis Price Performance

Shares of NASDAQ EXEL traded up $0.33 during trading on Friday, hitting $37.72. The stock had a trading volume of 1,906,288 shares, compared to its average volume of 3,769,804. Exelixis, Inc. has a 12 month low of $25.12 and a 12 month high of $49.62. The company has a market capitalization of $10.15 billion, a PE ratio of 18.13, a PEG ratio of 0.78 and a beta of 0.29. The firm has a fifty day moving average of $42.41 and a two-hundred day moving average of $38.97.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm's revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.84 earnings per share. On average, equities analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.